Vermillion (NASDAQ:VRML) posted its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04), Morningstar.com reports. The business had revenue of $0.77 million during the quarter. Vermillion had a negative return on equity of 201.03% and a negative net margin of 398.14%.
Shares of VRML traded down $0.06 during mid-day trading on Friday, hitting $0.57. The company’s stock had a trading volume of 103,000 shares, compared to its average volume of 123,418. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.74 and a quick ratio of 5.70. Vermillion has a 1-year low of $0.45 and a 1-year high of $2.10.
In other Vermillion news, CEO Valerie Barber Palmieri purchased 97,000 shares of Vermillion stock in a transaction dated Friday, August 17th. The stock was acquired at an average cost of $0.52 per share, with a total value of $50,440.00. Following the acquisition, the chief executive officer now directly owns 178,063 shares of the company’s stock, valued at $92,592.76. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Robert Harry Beechey purchased 100,000 shares of Vermillion stock in a transaction dated Tuesday, August 14th. The stock was acquired at an average cost of $0.52 per share, with a total value of $52,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders bought 291,100 shares of company stock valued at $157,931 and sold 33,473 shares valued at $16,837. 4.25% of the stock is owned by company insiders.
WARNING: This article was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.wkrb13.com/2018/11/10/vermillion-vrml-releases-quarterly-earnings-results-hits-expectations.html.
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
Featured Article: Penny Stocks, What You Need To Know
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.